Quick Summary
Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd (GSK) announced on September 3, 2024, that it has received an income tax refund of Rs 222.23 crore for the assessment year 2022-23, following an order issued by the Income Tax Department under Section 143(3). The refund includes interest and was disclosed in a stock exchange filing by the company. In other financial updates, GSK Pharmaceuticals reported a robust 37.8% year-on-year (YoY) increase in net profit for the first quarter en
Daily Limit Reached
You have reached your daily limit of 2 Free News
Subscribe to CCI PRO for unlimited access
Why Upgrade to CCI PRO?
- No Ads
- WhatsApp Community
- Daily E-Newsletter
- Unlimited News Access
- Profile Visitors
- Link Social Profiles
- Featured Job Posts
- Pro Badge
- Expert GST Guidance
- Unlimited Forum Replies
- Download Content in PDF
1 Year PLAN
1999
(Excl. of GST ₹359)
2 Years PLAN
3499
(Excl. of GST ₹629)
BEST VALUE
3 Years PLAN
4999
(Excl. of GST ₹899)
View all CCI PRO benefits
Already a PRO member? Login here for an ad-free experience. 07941056694
FAQ :
GlaxoSmithKline Pharmaceuticals received an income tax refund of Rs 222.23 crore.
The tax refund is for the assessment year 2022-23.
GSK Pharmaceuticals reported a net profit of Rs 182.3 crore for the first quarter ending June 30, 2024.
GSK's growth was driven by key brands like Calpol, Augmentin, and T-Bact, which gained market share, and an impressive 57% increase in its respiratory portfolio.
Revenue saw a 7% rise, climbing to Rs 814.7 crore from Rs 761.7 crore in the previous fiscal period.
CAclubindia
